Drug Profile
Research programme: protein kinase inhibitors - Asana BioSciences
Alternative Names: ASN-006Latest Information Update: 28 Dec 2019
Price :
$50
*
At a glance
- Originator Asana BioSciences
- Class Antineoplastics
- Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors; Src-Family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 02 Nov 2015 Preclinical trials in Cancer in USA (Parenteral)